Comprehensive Market Analysis Report: Global Metabotropic Glutamate Receptor 2 (mGluR2) Modulators Market (2026-2036)
1. Executive Summary
The global Metabotropic Glutamate Receptor 2 (mGluR2) modulators market represents a high-potential, innovative segment within the central nervous system (CNS) therapeutics landscape. mGluR2, a key regulator of glutamatergic neurotransmission, has emerged as a promising target for disorders with significant unmet needs, including schizophrenia, depression, and anxiety. This report provides a refined analysis of the market status and forecast from 2026 to 2036, evaluating the size, key innovators, therapeutic segmentation, and regional dynamics. The market is characterized by a transition from early-stage research to late-stage clinical validation, with growth driven by the pursuit of novel, non-dopaminergic mechanisms with improved safety profiles.
2. Market Overview
-
Market Valuation: The global mGluR2 modulators market is projected to experience substantial growth from 2026 to 2036, reaching a significant market value by the end of the forecast period, driven by a high Compound Annual Growth Rate (CAGR) upon successful product approvals.
-
Base Year: 2025
-
Forecast Period: 2026 - 2036
-
Key Drivers: High unmet need in psychiatric and neurological disorders, the novel mechanism of action offering potential advantages over current standards of care, strong investment in neuroscience R&D, and promising clinical data from late-stage candidates.
-
Primary Challenges: High clinical trial failure rates inherent to CNS drug development, complexity in proving efficacy for subjective psychiatric endpoints, regulatory hurdles for novel mechanisms, and future competition from other emerging neuro-modulatory therapies.
3. Key Market Players
The competitive landscape features a mix of specialized biotech firms and large pharmaceutical companies with active neuroscience pipelines.
-
Pipeline Leaders & Key Innovators:
-
Johnson & Johnson (Janssen): Developer of JNJ-40411813/ADX-71149 (an mGluR2 positive allosteric modulator) in Phase 2 for major depressive disorder and anxiety.
-
Eli Lilly and Company: Active in glutamate research; previously investigated LY-2607540 and related compounds.
-
Merck & Co Inc. (MSD): Has historical and potential ongoing research in mGluR targets.
-
Addex Therapeutics Ltd: A leader in allosteric modulation technology, with programs focused on mGluR2 and other receptors.
-
Domain Therapeutics SA: Specializes in GPCR drug discovery, including mGluR targets.
-
Denovo Biopharma LLC: Utilizes biomarker-driven development for CNS drugs, including mGluR2-related assets.
-
Bristol-Myers Squibb Company: Maintains neuroscience research interests.
-
-
Other Notable Entities:
-
Neurocrine Biosciences, Inc. (Potential interest in novel CNS mechanisms)
-
Takeda Pharmaceutical Company Limited (Strong neuroscience division)
-
BioXcel Therapeutics, Inc. (AI-driven CNS pipeline development)
-
Compass Pathways plc (Psychedelic research intersecting with glutamatergic pathways)
-
4. Market Segmentation Analysis
4.1 By Drug Class & Mechanism
-
Positive Allosteric Modulators (PAMs): The leading and most advanced segment. Compounds like JNJ-40411813 enhance receptor function only in the presence of glutamate, preserving physiological signaling and offering a favorable safety window.
-
Agonists: Directly activate the receptor. May carry a higher risk of tachyphylaxis or desensitization compared to PAMs.
-
Negative Allosteric Modulators (NAMs) & Antagonists: Primarily in research stages for potential applications in cognitive disorders, representing a future segment.
4.2 By Therapeutic Application
-
Schizophrenia (Adjunctive & Monotherapy): The most advanced indication. Targeting negative/cognitive symptoms and offering an alternative to antipsychotics with different side-effect profiles.
-
Major Depressive Disorder (MDD) & Treatment-Resistant Depression: High-growth potential segment for patients inadequately served by monoaminergic antidepressants.
-
Generalized Anxiety Disorder (GAD) & Other Anxiety Disorders: Targeted for patients seeking non-benzo-diazepine anxiolytics.
-
Chronic Pain (Neuropathic): Early-stage exploration based on glutamate's role in central sensitization.
-
Substance Use Disorders: Investigational for disorders like cocaine addiction, where glutamatergic dysregulation is implicated.
4.3 By Development Stage
-
Clinical-Stage (Phase 2/3): Comprises assets with proof-of-concept data, representing near-to-mid-term market potential.
-
Preclinical/Discovery-Stage: Encompasses novel compounds and next-generation modulators, indicating long-term pipeline vitality.
5. Regional Analysis
-
North America: Dominant market share expected due to high CNS drug adoption rates, premium pricing models, concentrated biopharma R&D activity, and a streamlined regulatory pathway (FDA) for breakthrough therapies.
-
Europe: Strong second market with significant academic research in neuroscience and established regulatory frameworks (EMA). Market uptake will be influenced by country-specific health technology assessments (HTA).
-
Asia-Pacific: Fastest-growing regional market over the forecast period. Growth is fueled by rising awareness of mental health, increasing healthcare investment, large patient populations, and the expansion of clinical trial sites by global players.
-
Latin America, Middle East & Africa: Nascent markets where growth is dependent on the successful launch and tiered pricing strategies in established regions first, followed by gradual market entry.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants: Moderate to High for biotech startups due to strong scientific interest and venture funding in novel neuroscience targets. Barriers include high R&D costs and complex clinical trials.
-
Bargaining Power of Suppliers: Low for standard materials. Moderate for specialized CROs with expertise in CNS clinical trials and biomarker development.
-
Bargaining Power of Buyers: Very High. Payers (government and private insurers) hold significant power in psychiatric drug markets and will demand compelling cost-effectiveness data for premium-priced novel agents.
-
Threat of Substitutes: High. Competition includes established generic antipsychotics/antidepressants, other novel CNS mechanisms in development (e.g., NMDA modulators, 5-HT2A agonists), and non-pharmacological interventions.
-
Industry Rivalry: Currently moderate but intensifying. Rivalry is based on clinical data, intellectual property for specific chemotypes, and the race to secure first-in-class or best-in-class status in key indications.
7. SWOT Analysis
-
Strengths: Novel mechanism addressing core pathophysiology of several disorders, potential for improved cognitive and safety profiles, strong patent protection for new chemical entities, high unmet need.
-
Weaknesses: Unproven long-term commercial success, risk of clinical trial failures in complex psychiatric conditions, potentially smaller initial target patient population (e.g., treatment-resistant).
-
Opportunities: Expansion into large adjacent indications (MDD, anxiety), development of companion diagnostics for patient stratification, combination therapy approaches with standard care.
-
Threats: Stringent regulatory requirements for proving clinically meaningful benefit, payer pushback on pricing, competition from rapid-acting antidepressants and digital therapeutics, and potential unforeseen side effects.
8. Trend Analysis
-
Precision Psychiatry Focus: Increasing integration of biomarker strategies (e.g., fMRI, EEG, genetic markers) to identify patient subgroups most likely to respond to mGluR2 modulation.
-
Adjunctive Therapy Paradigm: Initial market entry likely as an add-on to existing therapies, building evidence before potential monotherapy use.
-
Focus on Cognitive & Negative Symptoms: Differentiation from current drugs by demonstrating efficacy in symptom domains poorly addressed by existing treatments (e.g., cognitive impairment in schizophrenia).
-
Cross-Indication Exploration: Leveraging the fundamental role of glutamate to explore utility across a spectrum of neuropsychiatric conditions from a single platform.
9. Market Drivers & Challenges
-
Drivers:
-
Limitations of current monoaminergic antidepressants and antipsychotics (efficacy gaps, side effects).
-
Validation of the glutamatergic hypothesis of mood and psychotic disorders.
-
Successful clinical proof-of-concept data from leading candidates.
-
Growing societal acceptance and prioritization of mental health treatment.
-
-
Challenges:
-
Demonstrating robust and reproducible efficacy in placebo-controlled trials for psychiatric conditions.
-
Defining and achieving clinically meaningful endpoints that satisfy regulators and payers.
-
Commercial positioning and education in crowded, genericized markets.
-
Navigating diverse global reimbursement landscapes for chronic mental health therapies.
-
10. Value Chain Analysis
-
Target Discovery & Validation: Academic and industry research establishing mGluR2's role in disease pathophysiology.
-
Drug Discovery & Preclinical Development: High-throughput screening and medicinal chemistry to develop selective PAMs/NAMs with optimal drug-like properties.
-
Clinical Development: Complex, multi-phase trials requiring specialized psychiatric rating scales, patient recruitment networks, and often long-term safety follow-up.
-
Regulatory & Market Access: Engaging with regulators on novel endpoints. Developing comprehensive value dossiers that include health economic and quality-of-life data for payers.
-
Manufacturing: Standard small-molecule synthesis, though may require specialized chemistry for complex allosteric modulators.
-
Commercialization & Marketing: Targeted engagement with psychiatrists and neurologists. Requires substantial education on novel mechanisms. Potential for direct-to-patient disease awareness campaigns.
-
Post-Marketing Surveillance & Lifecycle Management: Critical for monitoring long-term CNS safety and exploring label expansions into new indications.
11. Strategic Recommendations for Stakeholders
-
For Pharmaceutical Companies: Prioritize rigorous biomarker strategies to de-risk clinical trials and enable targeted therapy. Invest in high-quality health economics and outcomes research (HEOR) from Phase 2. Explore combination trials to demonstrate synergistic benefits.
-
For Investors: Focus on companies with strong, clinically validated allosteric modulator platforms and clear, biomarker-enriched clinical pathways. Management's experience in CNS drug development and commercialization is critical.
-
For Healthcare Providers (Psychiatrists/Neurologists): Engage with clinical trials to gain early experience. Stay informed on glutamatergic mechanisms to prepare for a potential paradigm shift in treatment approaches for complex patients.
-
For Payers & Policymakers: Develop frameworks for evaluating the value of drugs targeting high-unmet-need populations (e.g., treatment-resistant depression). Consider outcomes-based agreements to manage uncertainty while ensuring patient access.
-
For Patients & Advocacy Groups: Support participation in clinical trials to accelerate development. Advocate for research funding into novel mechanisms and for insurance coverage of new, effective treatments.
Table of Contents
Global Metabotropic Glutamate Receptor 2 Market Research Report 2026
1 Industry Overview of Metabotropic Glutamate Receptor 2
1.1 Definition and Specifications of Metabotropic Glutamate Receptor 2
1.1.1 Definition of Metabotropic Glutamate Receptor 2
1.1.2 Specifications of Metabotropic Glutamate Receptor 2
1.2 Classification of Metabotropic Glutamate Receptor 2
1.2.1 LY-2607540
1.2.2 BMT-133218
1.2.3 DT-2442
1.2.4 JNJ-40411813
1.2.5 Others
1.3 Applications of Metabotropic Glutamate Receptor 2
1.3.1 Anxiety Disorders
1.3.2 Depression
1.3.3 Schizophrenia
1.3.4 Chronic Pain
1.3.5 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Metabotropic Glutamate Receptor 2
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Metabotropic Glutamate Receptor 2
2.3 Manufacturing Process Analysis of Metabotropic Glutamate Receptor 2
2.4 Industry Chain Structure of Metabotropic Glutamate Receptor 2
3 Technical Data and Manufacturing Plants Analysis of Metabotropic Glutamate Receptor 2
3.1 Capacity and Commercial Production Date of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
3.3 R&D Status and Technology Source of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
4 Global Metabotropic Glutamate Receptor 2 Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Metabotropic Glutamate Receptor 2 Capacity and Growth Rate Analysis
4.2.2 Metabotropic Glutamate Receptor 2 Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Metabotropic Glutamate Receptor 2 Sales and Growth Rate Analysis
4.3.2 Metabotropic Glutamate Receptor 2 Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Metabotropic Glutamate Receptor 2 Sales Price
4.4.2 Metabotropic Glutamate Receptor 2 Sales Price Analysis (Company Segment)
5 Metabotropic Glutamate Receptor 2 Regional Market Analysis
5.1 North America Metabotropic Glutamate Receptor 2 Market Analysis
5.1.1 North America Metabotropic Glutamate Receptor 2 Market Overview
5.1.2 North America E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.1.4 North America Metabotropic Glutamate Receptor 2 Market Share Analysis
5.2 Europe Metabotropic Glutamate Receptor 2 Market Analysis
5.2.1 Europe Metabotropic Glutamate Receptor 2 Market Overview
5.2.2 Europe E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.2.4 Europe Metabotropic Glutamate Receptor 2 Market Share Analysis
5.3 China Metabotropic Glutamate Receptor 2 Market Analysis
5.3.1 China Metabotropic Glutamate Receptor 2 Market Overview
5.3.2 China E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.3.4 China Metabotropic Glutamate Receptor 2 Market Share Analysis
5.4 Japan Metabotropic Glutamate Receptor 2 Market Analysis
5.4.1 Japan Metabotropic Glutamate Receptor 2 Market Overview
5.4.2 Japan E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.4.4 Japan Metabotropic Glutamate Receptor 2 Market Share Analysis
5.5 Southeast Asia Metabotropic Glutamate Receptor 2 Market Analysis
5.5.1 Southeast Asia Metabotropic Glutamate Receptor 2 Market Overview
5.5.2 Southeast Asia E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.5.4 Southeast Asia Metabotropic Glutamate Receptor 2 Market Share Analysis
5.6 India Metabotropic Glutamate Receptor 2 Market Analysis
5.6.1 India Metabotropic Glutamate Receptor 2 Market Overview
5.6.2 India E Metabotropic Glutamate Receptor 2 Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Metabotropic Glutamate Receptor 2 Sales Price Analysis
5.6.4 India Metabotropic Glutamate Receptor 2 Market Share Analysis
6 Global E Metabotropic Glutamate Receptor 2 Segment Market Analysis (by Type)
6.1 Global E Metabotropic Glutamate Receptor 2 Sales by Type
6.2 Different Types of Metabotropic Glutamate Receptor 2 Product Interview Price Analysis
6.3 Different Types of Metabotropic Glutamate Receptor 2 Product Driving Factors Analysis
6.3.1 LY-2607540 Growth Driving Factor Analysis
6.3.2 BMT-133218 Growth Driving Factor Analysis
6.3.3 DT-2442 Growth Driving Factor Analysis
6.3.4 JNJ-40411813 Growth Driving Factor Analysis
6.3.5 Others Growth Driving Factor Analysis
7 Global E Metabotropic Glutamate Receptor 2 Segment Market Analysis (by Application)
7.1 Global E Metabotropic Glutamate Receptor 2 Consumption by Application
7.2 Different Application of Metabotropic Glutamate Receptor 2 Product Interview Price Analysis
7.3 Different Application of Metabotropic Glutamate Receptor 2 Product Driving Factors Analysis
7.3.1 Anxiety Disorders of Metabotropic Glutamate Receptor 2 Growth Driving Factor Analysis
7.3.2 Depression of Metabotropic Glutamate Receptor 2 Growth Driving Factor Analysis
7.3.3 Schizophrenia of Metabotropic Glutamate Receptor 2 Growth Driving Factor Analysis
7.3.4 Chronic Pain of Metabotropic Glutamate Receptor 2 Growth Driving Factor Analysis
7.3.5 Others of Metabotropic Glutamate Receptor 2 Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Metabotropic Glutamate Receptor 2
8.1 Addex Therapeutics Ltd
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.2 Bristol-Myers Squibb Company
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.3 Denovo Biopharma LLC
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.4 Domain Therapeutics SA
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.5 Eli Lilly and Company
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Eli Lilly and Company Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Eli Lilly and Company Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.6 Johnson & Johnson
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Johnson & Johnson Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Johnson & Johnson Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
8.7 Merck & Co Inc
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Merck & Co Inc Metabotropic Glutamate Receptor 2 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Merck & Co Inc Metabotropic Glutamate Receptor 2 Business Region Distribution Analysis
9 Development Trend of Analysis of Metabotropic Glutamate Receptor 2 Market
9.1 Global Metabotropic Glutamate Receptor 2 Market Trend Analysis
9.1.1 Global 2018-2025 Metabotropic Glutamate Receptor 2 Market Size (Volume and Value) Forecast
9.1.2 Global 2018-2025 Metabotropic Glutamate Receptor 2 Sales Price Forecast
9.2 Metabotropic Glutamate Receptor 2 Regional Market Trend
9.2.1 North America 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.2.2 Europe 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.2.3 China 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.2.4 Japan 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.2.5 Southeast Asia 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.2.6 India 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Forecast
9.3 Metabotropic Glutamate Receptor 2 Market Trend (Product Type)
9.4 Metabotropic Glutamate Receptor 2 Market Trend (Application)
10 Metabotropic Glutamate Receptor 2 Marketing Type Analysis
10.1 Metabotropic Glutamate Receptor 2 Regional Marketing Type Analysis
10.2 Metabotropic Glutamate Receptor 2 International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Metabotropic Glutamate Receptor 2 by Region
10.4 Metabotropic Glutamate Receptor 2 Supply Chain Analysis
11 Consumers Analysis of Metabotropic Glutamate Receptor 2
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Metabotropic Glutamate Receptor 2 Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Metabotropic Glutamate Receptor 2
Table Product Specifications of Metabotropic Glutamate Receptor 2
Table Classification of Metabotropic Glutamate Receptor 2
Figure Global Production Market Share of Metabotropic Glutamate Receptor 2 by Type in
Figure LY-2607540 Picture
Table Major Manufacturers of LY-2607540
Figure BMT-133218 Picture
Table Major Manufacturers of BMT-133218
Figure DT-2442 Picture
Table Major Manufacturers of DT-2442
Figure JNJ-40411813 Picture
Table Major Manufacturers of JNJ-40411813
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Metabotropic Glutamate Receptor 2
Figure Global Consumption Volume Market Share of Metabotropic Glutamate Receptor 2 by Application in
Figure Anxiety Disorders Examples
Table Major Consumers in Anxiety Disorders
Figure Depression Examples
Table Major Consumers in Depression
Figure Schizophrenia Examples
Table Major Consumers in Schizophrenia
Figure Chronic Pain Examples
Table Major Consumers in Chronic Pain
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Metabotropic Glutamate Receptor 2 by Regions
Figure North America Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Figure Europe Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Figure China Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Figure Japan Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Figure Southeast Asia Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Figure India Metabotropic Glutamate Receptor 2 Market Size (Million USD) (2013-2025)
Table Metabotropic Glutamate Receptor 2 Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Metabotropic Glutamate Receptor 2 in
Figure Manufacturing Process Analysis of Metabotropic Glutamate Receptor 2
Figure Industry Chain Structure of Metabotropic Glutamate Receptor 2
Table Capacity and Commercial Production Date of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
Table Manufacturing Plants Distribution of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
Table R&D Status and Technology Source of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
Table Raw Materials Sources Analysis of Global Metabotropic Glutamate Receptor 2 Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Metabotropic Glutamate Receptor 2 E
Figure Global E Metabotropic Glutamate Receptor 2 Market Size (Volume) and Growth Rate
Figure Global E Metabotropic Glutamate Receptor 2 Market Size (Value) and Growth Rate
Table E Global Metabotropic Glutamate Receptor 2 Capacity and Growth Rate
Table Global Metabotropic Glutamate Receptor 2 Capacity (K Pcs) List (Company Segment)
Table E Global Metabotropic Glutamate Receptor 2 Sales (K Pcs) and Growth Rate
Table Global Metabotropic Glutamate Receptor 2 Sales (K Pcs) List (Company Segment)
Table E Global Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Table Global Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure North America E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure North America Metabotropic Glutamate Receptor 2 Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure Europe E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure Europe Metabotropic Glutamate Receptor 2 Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure China E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure China Metabotropic Glutamate Receptor 2 Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure Japan E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure Japan Metabotropic Glutamate Receptor 2 Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure Southeast Asia E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure Southeast Asia Metabotropic Glutamate Receptor 2 Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Metabotropic Glutamate Receptor 2 E
Figure India E Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs)
Figure India Metabotropic Glutamate Receptor 2 Sales Market Share
Table Global E Metabotropic Glutamate Receptor 2 Sales (K Pcs) by Type
Table Different Types Metabotropic Glutamate Receptor 2 Product Interview Price
Table Global E Metabotropic Glutamate Receptor 2 Sales (K Pcs) by Application
Table Different Application Metabotropic Glutamate Receptor 2 Product Interview Price
Table Addex Therapeutics Ltd Information List
Table Product Overview
Table Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Bristol-Myers Squibb Company Information List
Table Product Overview
Table Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Denovo Biopharma LLC Information List
Table Product Overview
Table Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Domain Therapeutics SA Information List
Table Product Overview
Table Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Eli Lilly and Company Information List
Table Product Overview
Table Eli Lilly and Company Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Eli Lilly and Company Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Johnson & Johnson Information List
Table Product Overview
Table Johnson & Johnson Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Johnson & Johnson Metabotropic Glutamate Receptor 2 Business Region Distribution
Table Merck & Co Inc Information List
Table Product Overview
Table Merck & Co Inc Metabotropic Glutamate Receptor 2 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Merck & Co Inc Metabotropic Glutamate Receptor 2 Business Region Distribution
Figure Global 2018-2025 Metabotropic Glutamate Receptor 2 Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2018-2025 Metabotropic Glutamate Receptor 2 Market Size (Million USD) and Growth Rate Forecast
Figure Global 2018-2025 Metabotropic Glutamate Receptor 2 Sales Price (USD/Pcs) Forecast
Figure North America 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2018-2025 Metabotropic Glutamate Receptor 2 Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Metabotropic Glutamate Receptor 2 by Type 2018-2025
Table Global Consumption Volume (K Pcs) of Metabotropic Glutamate Receptor 2 by Application 2018-2025
Table Traders or Distributors with Contact Information of Metabotropic Glutamate Receptor 2 by Region
Key Market Players
The competitive landscape features a mix of specialized biotech firms and large pharmaceutical companies with active neuroscience pipelines.
-
Pipeline Leaders & Key Innovators:
-
Johnson & Johnson (Janssen): Developer of JNJ-40411813/ADX-71149 (an mGluR2 positive allosteric modulator) in Phase 2 for major depressive disorder and anxiety.
-
Eli Lilly and Company: Active in glutamate research; previously investigated LY-2607540 and related compounds.
-
Merck & Co Inc. (MSD): Has historical and potential ongoing research in mGluR targets.
-
Addex Therapeutics Ltd: A leader in allosteric modulation technology, with programs focused on mGluR2 and other receptors.
-
Domain Therapeutics SA: Specializes in GPCR drug discovery, including mGluR targets.
-
Denovo Biopharma LLC: Utilizes biomarker-driven development for CNS drugs, including mGluR2-related assets.
-
Bristol-Myers Squibb Company: Maintains neuroscience research interests.
-
-
Other Notable Entities:
-
Neurocrine Biosciences, Inc. (Potential interest in novel CNS mechanisms)
-
Takeda Pharmaceutical Company Limited (Strong neuroscience division)
-
BioXcel Therapeutics, Inc. (AI-driven CNS pipeline development)
-
Compass Pathways plc (Psychedelic research intersecting with glutamatergic pathways)
-
4. Market Segmentation Analysis
4.1 By Drug Class & Mechanism
-
Positive Allosteric Modulators (PAMs): The leading and most advanced segment. Compounds like JNJ-40411813 enhance receptor function only in the presence of glutamate, preserving physiological signaling and offering a favorable safety window.
-
Agonists: Directly activate the receptor. May carry a higher risk of tachyphylaxis or desensitization compared to PAMs.
-
Negative Allosteric Modulators (NAMs) & Antagonists: Primarily in research stages for potential applications in cognitive disorders, representing a future segment.
4.2 By Therapeutic Application
-
Schizophrenia (Adjunctive & Monotherapy): The most advanced indication. Targeting negative/cognitive symptoms and offering an alternative to antipsychotics with different side-effect profiles.
-
Major Depressive Disorder (MDD) & Treatment-Resistant Depression: High-growth potential segment for patients inadequately served by monoaminergic antidepressants.
-
Generalized Anxiety Disorder (GAD) & Other Anxiety Disorders: Targeted for patients seeking non-benzo-diazepine anxiolytics.
-
Chronic Pain (Neuropathic): Early-stage exploration based on glutamate's role in central sensitization.
-
Substance Use Disorders: Investigational for disorders like cocaine addiction, where glutamatergic dysregulation is implicated.
4.3 By Development Stage
-
Clinical-Stage (Phase 2/3): Comprises assets with proof-of-concept data, representing near-to-mid-term market potential.
-
Preclinical/Discovery-Stage: Encompasses novel compounds and next-generation modulators, indicating long-term pipeline vitality.
